| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 10,694.1 | 10,332 | 7,400.3 | 5,775.2 | 5,301 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 10,694.1 | 10,332 | 7,400.3 | 5,775.2 | 5,301 |
Other Operating Income | 150.6 | 506.6 | 0 | 0 | 0 |
Other Income | 1,247.4 | 838.1 | 221 | 145.4 | 56.1 |
Total Income | 12,092.1 | 11,676.7 | 7,621.3 | 5,920.6 | 5,357.1 |
Total Expenditure | 8,756.6 | 8,561.3 | 6,301.2 | 4,620.9 | 4,100.6 |
PBIDT | 3,335.5 | 3,115.4 | 1,320.1 | 1,299.7 | 1,256.5 |
Interest | 685 | 747.4 | 170.2 | 57.1 | 23.8 |
PBDT | 2,650.5 | 2,368 | 1,149.9 | 1,242.6 | 1,232.7 |
Depreciation | 1,250.7 | 1,161.8 | 749.4 | 602 | 530.8 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 383.1 | 178.4 | 280.9 | 152.9 | 152.1 |
Deferred Tax | 46.7 | -47.1 | -108.9 | 0 | 0 |
Reported Profit After Tax | 970 | 1,074.9 | 228.5 | 487.7 | 549.8 |
Minority Interest After NP | 301.2 | 187.9 | 79 | 77.9 | 62.5 |
Net Profit after Minority Interest | 668.8 | 887 | 149.5 | 409.8 | 487.3 |
Extra-ordinary Items | 52.73 | -2.39 | -86.12 | -53.37 | 0 |
Adjusted Profit After Extra-ordinary item | 616.07 | 889.39 | 235.62 | 463.17 | 487.3 |
EPS (Unit Curr.) | 5.59 | 7.42 | 1.25 | 3.44 | 4.11 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 600.3 | 600.3 | 600.3 | 600.3 | 600 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.19 | 30.15 | 17.83 | 22.5 | 23.7 |
PBDTM(%) | 24.78 | 22.91 | 15.53 | 21.51 | 23.25 |
PATM(%) | 9.07 | 10.4 | 3.08 | 8.44 | 10.37 |
The inspection, held between August 26 and September 3, covered drug substance manufacturing units, quality control labs, microbiology labs and warehouses.
The drug shall be used to treat diet and exercise for improvement of glycemic control in adults with type 2 diabetes.
Here are some of the stocks that may see significant price movement today: Interglobe Aviation, Tata Consultancy, Oil India, etc.
Biosimilars revenue grew 18% YoY to ₹2,458 crore in the quarter. This growth was driven by sustained global demand
As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Here are some of the stocks that may see significant price movement today: Hyundai Motor, Biocon, Zee Entertainment, etc.
Biocon has appointed Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India as lead advisors for the transaction
In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.
As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
